===============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
FORM 8-K
-----------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 11, 2005
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-30929 13-4087132
---------------------------- ----------- ------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)
(212) 531-5965
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act.
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
[ ] Pre-commencement communications pursuant to Rule 14d-2b under the
Exchange Act.
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act.
===============================================================================
Item 8.01. Other Events
On November 11, 2005, Keryx Biopharmaceuticals, Inc. issued a press
release announcing the final results from its Phase 2 clinical study for KRX-101
(sulodexide gelcaps) for the treatment of diabetic nephropathy. A copy of such
press release is being filed as Exhibit 99.1 to this report and is incorporated
herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is filed as a part of this report:
Exhibit
Number Description
------- -----------
99.1 Press Release dated November 11, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Keryx Biopharmaceuticals, Inc.
(Registrant)
Date: November 14, 2005
By: /s/ Ron Bentsur
-------------------------------
Ron Bentsur
Vice President, Finance and
Investor Relations
INDEX TO EXHIBITS
Exhibit
Number Description
------- -----------
99.1 Press Release dated November 11, 2005.